Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT04642352
Status
Recruiting
Apply to this trial

Conditions

  • Cough

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • superior laryngeal nerve block — DRUG
    A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.

Study Details

The purpose of this study is to evaluate if office-based injection of a local anesthetic/steroid combination at the area of one superior laryngeal nerve can decrease cough frequency and alleviate symptoms of chronic cough in patients with neurogenic cough.

Key Dates

Start date
Jan 3, 2022
Status verified
Apr 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: SLN intervention group
    Participants will undergo a superior laryngeal nerve (SLN) block

Primary Outcome Measure

Change in score on the Leicester Cough Questionnaire [ Time Frame: Baseline to 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233
Blake Simpson, MD
[email protected]
(205) 801-7864

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies